Molbio’s FY26 test-kit volumes rose to 17.56 million units
Key highlights
- Molbio sold 17.56 million test kits in FY26, versus 12.24 million in FY25.
- Test kits contributed 73.98% of Molbio’s FY26 product revenue, compared with 26.02% for devices.
- Molbio reported more than 12,500 Truenat devices sold globally and an India installed base of about 8,000 to 10,000.
- Molbio reported 39 million annual Truenat test-kit capacity and 58.25% FY26 utilisation.
powered by IRIS

Molbio sold 17.56 million test kits in FY26, up from 12.24 million in FY25, while proprietary kits accounted for 73.98% of product revenue. The FY24-to-FY26 volume trend, which Molbio presents as about 41% compound annual growth rate, shows that repeat kit consumption represented the larger product-revenue component than device sales.
Know Molbio Diagnostics inside out
Results, valuation, peers and who's buying, in one view.
How quickly did Molbio’s test-kit volumes grow?
Molbio’s test-kit sales rose to 17.56 million units in FY26 from 8.8 million in FY24, an increase of 8.76 million units over two financial years. Molbio describes the FY24-FY26 trajectory as approximately 41% compound annual growth rate, or CAGR, in test-kit volumes, with FY25 sales of 12.24 million units between the two periods.
The annual sequence shows that the absolute increase was larger in FY26. Sales added 3.44 million units from FY24 to FY25, then added 5.32 million units from FY25 to FY26. Each Truenat test requires a disease-specific, single-use kit rather than only access to an installed device.
Molbio’s consumable includes cartridge-based sample preparation, pre-loaded polymerase chain reaction, or PCR, reagents, and a Truenat micro-PCR chip. The kits are ready to use and designed exclusively for the Truenat platform, meaning the reported 17.56 million-unit FY26 volume measures proprietary consumables rather than third-party tests run on the machines.
Why were test kits the larger part of Molbio’s product revenue?
Molbio reported that test kits contributed 73.98% of product revenue in FY26, compared with 26.02% for devices. The mix is consistent with Molbio’s stated model, in which device placement establishes the platform and each subsequent test consumes a disposable proprietary kit.
The product-revenue mix shifted from FY24 and then remained similar in FY26. Test kits represented 67.78% of product revenue in FY24, rose to 74.31% in FY25 and eased by 0.33 percentage points to 73.98% in FY26. Devices moved in the opposite direction, declining from 32.22% in FY24 to 25.69% in FY25 before reaching 26.02% in FY26.
Molbio reported a blended average FY26 kit realisation of Rs 589, while blended average device realisation was Rs 8.05404 lakh. The two measures relate to different products: UnoDx, Duo and Quattro devices respectively handle one, two and four tests, while a kit supports one test. Molbio does not disclose kit-level gross margin or customer-level repeat-purchase rates on these pages.
Got a follow-up? Ask IRIS
What installed base supports Molbio’s consumable model?
Molbio had sold more than 12,500 Truenat devices globally and cited an India installed base of about 8,000 to 10,000 devices in FY26. Its stated operating sequence is to deploy portable machines in hospitals, laboratories, primary health centres and mobile health programmes, process samples on-platform, and consume a proprietary kit for each test.
The platform’s test menu provides the mechanism that Molbio says can expand usage after a device is deployed. Molbio lists 43 assays across 30 diseases, including tuberculosis, hepatitis B and C, HIV, human papillomavirus, COVID-19, dengue and influenza. Results are presented as available in about 60 minutes, and the same core platform can use disease-specific micro-PCR chips.
Manufacturing capacity provides additional context for the FY26 kit-volume figure. Molbio reported annual capacity of 39 million Truenat test kits across six manufacturing facilities in four locations, with FY26 test-kit capacity utilisation of 58.25%. Goa has two facilities making Truenat kits, while Visakhapatnam and Bengaluru make test-kit components alongside other products.
Has Molbio’s test-kit momentum continued into FY27?
Molbio sold 9.47 million test kits in H1 FY27, compared with 9.52 million in H1 FY26, a difference of 0.05 million units. The near-flat first-half comparison followed the FY26 total of 17.56 million units and means the operating dashboard does not show a year-on-year increase in first-half kit volumes.
Quarterly figures varied within H1 FY27. Q1 FY27 test-kit sales were 6.24 million units, while Q2 FY27 sales were 3.24 million units; Q2 FY26 had recorded 8.73 million units. In the same dashboard, devices sold fell to 559 in H1 FY27 from 860 in H1 FY26, and Q2 FY27 device sales were 395 versus 647 a year earlier.
Average kit realisation increased to Rs 602 in H1 FY27 from Rs 591 in H1 FY26. It was Rs 599 in Q1 FY27 and Rs 607 in Q2 FY27, compared with Rs 593 in Q2 FY26. Average device realisation was Rs 8.18 lakh in H1 FY27 versus Rs 8.03 lakh in H1 FY26, while Molbio reported FY26 device-manufacturing capacity of 5,400 units and utilisation of 42.30%.
Conclusion
Molbio’s disclosed figures show a consumables-weighted product model: test-kit volumes grew from 8.8 million in FY24 to 17.56 million in FY26, and kits supplied 73.98% of FY26 product revenue. The global base of more than 12,500 devices connects future kit use to platforms already sold, while the 43-assay, 30-disease menu provides multiple testing applications on that platform.
The next disclosed indicators to watch are utilisation and kit volumes in subsequent FY27 periods. Molbio identifies higher utilisation, additional assays and new geographies as avenues to lift kit sales, while its 39 million-unit annual kit capacity and 58.25% FY26 utilisation indicate available production capacity. The H1 FY27 comparison of 9.47 million kits versus 9.52 million a year earlier leaves the pace of renewed volume growth unresolved.


